Punjab launches AI screening program this week
1. Punjab launched India’s first large-scale AI screening program for cancer and eye disease. 2. The initiative aims to perform ...
1. Punjab launched India’s first large-scale AI screening program for cancer and eye disease. 2. The initiative aims to perform ...
Lilly unveils TuneLab AI platform for biotechs On September 9, 2025, Eli Lilly officially unveiled TuneLab, a federated AI platform ...
1. Cadonilimab plus chemotherapy significantly improved progression-free survival in patients with persistent, recurrent, or metastatic cervical cancer. 2. Common grade ...
1. In this modeling study, the cost-effectiveness and number needed to vaccinate of mid-adult human papillomavirus (HPV) vaccination improved when ...
1. 5-year progression-free survival was increased in the induction chemotherapy group compared to standard chemoradiotherapy. 2. Patients in the induction ...
1. 36-month overall survival was significantly greater in the pembrolizumab-chemoradiotherapy group compared to placebo-chemoradiotherapy. 2. Grade 3 or higher adverse ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-chemoradiotherapy group reported slightly ...
1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-chemoradiotherapy group reported slightly ...
1. For women with cervical intraepithelial neoplasia grade 2 (CIN2), the risk of preterm birth was similar for those who ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.